Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
2026-08-07 19:28
•Prosper Junior Bakiny •The Motley Fool
••••• •••• Axe Cap view
Pfizer's Weight-Loss Bet: A South African Perspective
Pfizer’s new weight-loss drug offers promise, but local investors should watch the rand and pharma sector closely.
Pfizer’s upcoming drug, berobenatide, is aiming to carve out a niche against established players like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Its monthly dosing is a practical edge, even if it doesn’t quite match the highest efficacy levels. For South African investors, the bigger question is how this plays out in rand terms. Pfizer’s US dollar revenues should benefit if the rand weakens, but South African pharma stocks aren’t directly exposed to this new obesity medication battle. Instead, watch sectors that tend to reflect global healthcare trends or currency swings, like Aspen or Adcock Ingram. The rand’s reaction to US dollar strength, especially USD/ZAR, will be key; a stronger dollar can squeeze profits and valuations locally. Pfizer’s 6.7% dividend yield is attractive but comes with execution risks, not least patent cliffs. If US healthcare regulation tightens or competitive pressure intensifies, Pfizer’s story might falter. Given SA’s local factors, this isn’t a direct buying call for JSE pharma stocks but a heads-up on currency and global healthcare themes. this is just our opinion and not financial advice
Watch USD/ZAR closely and consider currency-hedged exposure to global healthcare through ETFs or multinational pharma counters like Aspen. Avoid overcommitting to local pharma stocks purely on this story.
- USD/ZAR
- Aspen
- rand strengthening against the US dollar, reducing export revenue
- regulatory hurdles affecting Pfizer’s drug approval and pricing
5/10
Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.
Our take is based on reporting first published by The Motley Fool.